BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sacituzumab Tirumotecan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Sacituzumab Tirumotecan\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06448312-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06448312)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of SKB264 in Combination With Pembrolizumab Versus Pembro
 lizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lun
 g Cancer\nEstimated primary completion: November 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06448312
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06711900-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06711900)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of SKB264 in Combination With Pembrolizumab Versus Chemot
 herapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1
  Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Sm
 all Cell Lung Cancer\nEstimated primary completion: December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06711900
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07108816-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07108816)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Single-center\, Phase II Clinical Trial Evaluating the Efficacy
  of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvan
 t Therapy for PD-L1-positive\, Resectable Stage II to IIIB Non-small Cell 
 Lung Cancer (NSCLC)\nEstimated primary completion: 30 December 2026. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071088
 16
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05631262-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT05631262)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: SKB264 Monotherapy i
 n Selected Subjects With Advanced Solid Tumors\nEstimated primary completi
 on: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /sacituzumab-tirumotecan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05631262
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07579598-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07579598)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: ADC and SBRT for Rec
 urrent/Metastatic Salivary Gland Carcinoma\nEstimated primary completion: 
 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sac
 ituzumab-tirumotecan#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07579598
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06081959-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06081959)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Study of SKB264 for Locally Advanced\, Recurrent or Metas
 tatic HR+/HER2- Breast Cancer\nEstimated primary completion: 31 December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tiru
 motecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06081959
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07623577-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07623577)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Sac-TMT Combined Wit
 h Bevacizumab in TNBC With Brain Metastases\nEstimated primary completion:
  January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacitu
 zumab-tirumotecan#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07623577
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07561463-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07561463)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Sacituzumab Tirumote
 can for Pancreatic Cancer\nEstimated primary completion: 1 January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumoteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 561463
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07388875-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07388875)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Sacituzumab Tirumote
 can Plus Anlotinib in Previously Treated ES-SCLC\nEstimated primary comple
 tion: 1 February 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/sacituzumab-tirumotecan#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07388875
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07438600-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07438600)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Study of Sacituzumab Tirumotecan Combined With Toripalimab for Re
 sectable Stage II-IIIB NSCLC\nEstimated primary completion: 28 February 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirum
 otecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07438600
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06992739-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT06992739)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGF
 R-mutated\, Advanced Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary
  completion: March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06992739
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06279364-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06279364)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Breast Cancer.\nStudy: A St
 udy of SKB264 Versus Investigator's Choice Chemotherapy in Patients With U
 nresectable Recurrent or Metastatic Triple-Negative Breast Cancer\nEstimat
 ed primary completion: April 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06279364
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07139470-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20270415
DTEND;VALUE=DATE:20270416
SUMMARY:Sacituzumab Tirumotecan: Phase 1/2 readout est. (NCT07139470)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1/2\, Breast Cancer.\nStudy: Sa
 cituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast
  Cancer\nEstimated primary completion: 15 April 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07139470
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06670196-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06670196)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of SKB264 in Combination With Osimertinib Versus Osimerti
 nib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations\, L
 ocally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer\nEst
 imated primary completion: May 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06670196
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06074588-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20270510
DTEND;VALUE=DATE:20270511
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06074588)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previous
 ly Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (
 NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)\nEst
 imated primary completion: 10 May 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06074588
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07244926-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07244926)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced No
 n-Squamous Non-Small Cell Lung Cancer\nEstimated primary completion: June 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tir
 umotecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07244926
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05319730-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20270611
DTEND;VALUE=DATE:20270612
SUMMARY:Sacituzumab Tirumotecan: Phase 1/2 readout est. (NCT05319730)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1/2.\nStudy: A Study to Evaluat
 e Investigational Agents With or Without Pembrolizumab (MK-3475) in Partic
 ipants With Advanced Esophageal Cancer Previously Exposed to Programmed Ce
 ll Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatmen
 t (MK-3475-06B)\nEstimated primary completion: 11 June 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05319730
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07343479-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20270620
DTEND;VALUE=DATE:20270621
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07343479)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Ra
 diotherapy for EGFR-Mutant NSCLC Brain Metastases\nEstimated primary compl
 etion: 20 June 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 sacituzumab-tirumotecan#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07343479
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07179783-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07179783)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Sacituzumab Tirumote
 can in Combination With Tagitanlimab in the Treatment of Aggressive Varian
 t Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)\nEstima
 ted primary completion: 30 June 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07179783
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071337-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT07071337)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study of SKB264 Versus Investigator's Choice of Chemoth
 erapy in Subjects With Unresectable Locally Advanced\, Relapsed\, or Metas
 tatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
 \nEstimated primary completion: July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07071337
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07105852-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07105852)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Exploring the Safety
  and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the
  Treatment of Advanced Cholangiocarcinoma\nEstimated primary completion: 1
  July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzum
 ab-tirumotecan#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07105852
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07701122-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07701122)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Sacituzumab Tirumote
 can in Previously Treated TROP2-Positive Advanced Biliary Tract Cancer\nEs
 timated primary completion: 1 July 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07701122
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07789444-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07789444)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Sacituzumab Tirumotecan（Sac-TMT） and Brain Radotherapy for EG
 FR+ NSCLC With Brain Mets\nEstimated primary completion: 1 July 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07789
 444
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06312176-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20270711
DTEND;VALUE=DATE:20270712
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06312176)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study of Sacituzumab Tirumotecan (MK-2870) as a Single 
 Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of 
 Physician's Choice in Participants With HR+/HER2- Unresectable Locally Adv
 anced or Metastatic Breast Cancer (MK-2870-010)\nEstimated primary complet
 ion: 11 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sa
 cituzumab-tirumotecan#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06312176
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07077564-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20270720
DTEND;VALUE=DATE:20270721
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07077564)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: The Efficacy of TROP
 2-ADC in Advanced Extrapulmonary High-Grade Neuroendocrine Neoplasms Failu
 re of Standard Therapy\nEstimated primary completion: 20 July 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0707756
 4
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07258108-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07258108)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Sac-TMT Plus KL-A167 in PD-L1+\, HR+/HER2- Metastatic Bre
 ast Cancer After CDK4/6 Inhibitors\nEstimated primary completion: 30 July 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tir
 umotecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07258108
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07088211-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07088211)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Sacituzumab Tirumote
 can and Toripalimab in the First-line Treatment of HNSCC\nEstimated primar
 y completion: 1 August 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07088211
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07501169-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07501169)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Sacituzumab Tirumote
 can in Combination With Anlotinib in Previously Treated Patients With Exte
 nsive-Stage Small Cell Lung Cancer (ES-SCLC)\nEstimated primary completion
 : 31 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sac
 ituzumab-tirumotecan#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07501169
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07689292-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07689292)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Sac-TMT Combined Wit
 h Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/
 Gastroesophageal Junction Adenocarcinoma\nEstimated primary completion: 31
  August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituz
 umab-tirumotecan#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07689292
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07329322-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07329322)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Phase II Study of Sacituzumab Tirumotecan in Combination With Osi
 mertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal G
 rowth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer\nEstimated
  primary completion: 31 August 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07329322
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07703228-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07703228)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced D
 river Gene-Negative Non-Squamous NSCLC\nEstimated primary completion: 30 S
 eptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacitu
 zumab-tirumotecan#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07703228
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05642780-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT05642780)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: SKB264 in Combinatio
 n With Pembrolizumab in Subjects With Selected Solid Tumors\nEstimated pri
 mary completion: 30 November 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05642780
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07729033-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07729033)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: A Phase II Explorato
 ry Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Po
 sitive Advanced Biliary Tract Cancers Previously Treated With First-Line I
 mmunotherapy Combined With Chemotherapy.\nEstimated primary completion: De
 cember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzu
 mab-tirumotecan#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07729033
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07939204-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07939204)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: A Single-Arm Phase I
 I Clinical Study of Sacituzumab Tirumotecan Combined With a PD-1 Inhibitor
  as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma Af
 ter Failure of or Progression on Immunotherapy\nEstimated primary completi
 on: December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sa
 cituzumab-tirumotecan#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07939204
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07343453-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20271222
DTEND;VALUE=DATE:20271223
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07343453)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: A Single-Arm\, Phase
  II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan i
 n Second-Line and Subsequent Treatments for Advanced Thymic Epithelial Tum
 ors\nEstimated primary completion: 22 December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07343453
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07197008-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07197008)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generat
 ion EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Met
 astasis\nEstimated primary completion: 30 December 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07197008
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07314619-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07314619)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Ovarian Cancer.\nStudy: Pro
 spective\, Multicenter\, Single-Arm\, Phase Ⅱ Clinical Study on the Effi
 cacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Pl
 atinum-Resistant Recurrent Ovarian Cancer\nEstimated primary completion: 3
 0 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/saci
 tuzumab-tirumotecan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07314619
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07854509-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07854509)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI F
 ailure\nEstimated primary completion: 30 December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07854509
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07702305-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sacituzumab Tirumotecan: Phase 1 readout est. (NCT07702305)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1\, Non-Small Cell Lung Cancer.
 \nStudy: Safety and Efficacy of Intrathecal Sacituzumab Tirumotecan for Le
 ptomeningeal Metastasis in EGFR-TKI-Resistant Non-Small Cell Lung Cancer\n
 Estimated primary completion: 31 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07702305
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06049212-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sacituzumab Tirumotecan: Phase 1 readout est. (NCT06049212)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1\, Non-Small Cell Lung Cancer.
 \nStudy: Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combinati
 on With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-
 008)\nEstimated primary completion: 31 December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06049212
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06849492-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT06849492)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Breast Cancer.\nStudy: HIM 
 Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast 
 Cancer\nEstimated primary completion: 31 December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06849492
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686588-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07686588)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Sacituzumab Tirumote
 can Plus Immunotherapy for Recurrent or Metastatic Head and Neck Squamous 
 Cell Carcinoma\nEstimated primary completion: 31 December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07686588
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07811752-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07811752)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Sacituzumab Goviteca
 n Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Ca
 ncer\nEstimated primary completion: 31 December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07811752
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07068542-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sacituzumab Tirumotecan: Phase na readout est. (NCT07068542)
DESCRIPTION:Sacituzumab Tirumotecan\, phase na.\nStudy: Sacituzumab Tirumot
 ecan Combined With Immunotherapy in Advanced Thyroid Cancer\nEstimated pri
 mary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07068542
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07109284-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07109284)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Breast Cancer.\nStudy: SKB2
 64 Combined With KL-A167 Neoadjuvant Therapy for Early-stage\, High-risk E
 R+/HER2- Breast Cancer\nEstimated primary completion: January 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0710928
 4
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07341100-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07341100)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Study to Evaluate th
 e Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the P
 K of SKB264 in OC\nEstimated primary completion: January 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07341100
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07670013-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07670013)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: SKB264 Plus Glecirasib in Advanced KRAS G12C-Mutant NSCLC: A Phas
 e II Study\nEstimated primary completion: January 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07670013
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07348861-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07348861)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Cervical Cancer.\nStudy: A 
 Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With 
 Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer\nEstimate
 d primary completion: 1 January 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07348861
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06132958-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20280110
DTEND;VALUE=DATE:20280111
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06132958)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Endometrial Cancer.\nStudy:
  Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy
  Endometrial Cancer (MK-2870-005)\nEstimated primary completion: 10 Januar
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-t
 irumotecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06132958
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07466927-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20280115
DTEND;VALUE=DATE:20280116
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07466927)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Study of Multi-mode Thermal Therapy Combined With Immunot
 herapy In Patients With HER2-negative Breast Cancer With Liver Metastases\
 nEstimated primary completion: 15 January 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07466927
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07548060-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20280122
DTEND;VALUE=DATE:20280123
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07548060)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Phase II Study of Sacituzumab Tirumotecan in Combination With F
 urmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who 
 Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy\nEstimated 
 primary completion: 22 January 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07548060
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06170788-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20280125
DTEND;VALUE=DATE:20280126
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06170788)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizum
 ab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NS
 CLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (T
 PS) ≥ 50% (MK-2870-007)\nEstimated primary completion: 25 January 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotec
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6170788
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07244874-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07244874)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Breast Cancer.\nStudy: Sac-
 TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a
 /mTNBC\nEstimated primary completion: 30 January 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07244874
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07545213-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20280215
DTEND;VALUE=DATE:20280216
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07545213)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistan
 t Advanced NSCLC With Liver Metastasis\nEstimated primary completion: 15 F
 ebruary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituz
 umab-tirumotecan#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07545213
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07815197-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07815197)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Sacituzumab Tirumote
 can as Second-Line Treatment for Penile Cancer\nEstimated primary completi
 on: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacit
 uzumab-tirumotecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07815197
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07471776-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20280311
DTEND;VALUE=DATE:20280312
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07471776)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Study on Using TROP2-PET and 18F-FDG PET to Predict the E
 fficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer\nEstimated p
 rimary completion: 11 March 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07471776
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06483334-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Sacituzumab Tirumotecan: Phase 1/2 readout est. (NCT06483334)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1/2.\nStudy: A Study of Efficac
 y and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin 
 (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3
 475-04C/KEYMAKER-U04)\nEstimated primary completion: 31 March 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0648333
 4
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07324629-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07324629)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Sacituzumab Tirumote
 can in Participants With Locally Advanced or Metastatic Thymic Carcinoma\n
 Estimated primary completion: April 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07324629
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06445972-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20280509
DTEND;VALUE=DATE:20280510
SUMMARY:Sacituzumab Tirumotecan: Phase 1/2 readout est. (NCT06445972)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1/2.\nStudy: Substudy 06D: Comb
 ination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-
 3475-06D/Keymaker-U06)\nEstimated primary completion: 9 May 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06445972
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07438626-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07438626)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Phase II Trial of Sa
 cituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary C
 arcinoma\nEstimated primary completion: 1 June 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07438626
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06459180-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06459180)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Cervical Cancer.\nStudy: A 
 Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Trea
 tment of Physician's Choice as Second-line Treatment for Participants With
  Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101
 /ENGOT-cx20)\nEstimated primary completion: 15 June 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06459180
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07256236-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07256236)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Cervical Cancer.\nStudy: SK
 B264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer\nEstimated pri
 mary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07256236
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07375316-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07375316)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A ctDNA-guided Phase II Trial of Osimertinib in Combination With 
 Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Posit
 ive ctDNA After lead-in Osimertinib Monotherapy\nEstimated primary complet
 ion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sa
 cituzumab-tirumotecan#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07375316
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07371208-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07371208)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Breast Cancer.\nStudy: Mult
 icenter\, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in 
 Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Brea
 st Cancer\nEstimated primary completion: August 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07371208
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07458113-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07458113)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Breast Cancer.\nStudy: Sac-
 TMT for Active TNBC Brain Metastases\nEstimated primary completion: August
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-ti
 rumotecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07458113
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07697586-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07697586)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer\
 nEstimated primary completion: August 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07697586
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07157956-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20280812
DTEND;VALUE=DATE:20280813
SUMMARY:Sacituzumab Tirumotecan: Phase 1/2 readout est. (NCT07157956)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1/2.\nStudy: CVL006 Combination
  Therapy in Advanced Solid Tumors\nEstimated primary completion: 12 August
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-ti
 rumotecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07157956
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06305754-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20280817
DTEND;VALUE=DATE:20280818
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06305754)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplat
 in Combination Therapy in Participants With Epidermal Growth Factor (EGFR)
 -Mutated\, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Hav
 e Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)\nEstim
 ated primary completion: 17 August 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06305754
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07701681-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07701681)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Sacituzumab Tirumote
 can (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurren
 t or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesoph
 ageal Junction Adenocarcinoma\nEstimated primary completion: 1 September 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tiru
 motecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07701681
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07738757-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07738757)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: SKB264 Plus KL-A167 
 in MSI-H/dMMR Advanced Gynecological Malignancies\nEstimated primary compl
 etion: 1 September 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07738757
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07182721-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07182721)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Breast Cancer.\nStudy: SKB2
 64 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Prog
 ressing After T-DXd Treatment\nEstimated primary completion: 30 September 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tir
 umotecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07182721
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07850791-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07850791)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: A Prospective Study 
 of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Biliary Tract C
 ancer\nEstimated primary completion: October 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07850791
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07521670-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07521670)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Sacituzumab Tirumote
 can in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid
  Carcinoma (STRAP)\nEstimated primary completion: 31 October 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07521670
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06706219-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT06706219)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combin
 ation With Toripalimab in Patients With Initially Unresectable Stage III N
 SCLC\nEstimated primary completion: 30 November 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06706219
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07128693-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07128693)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: A Single-center\, Mu
 lticohort\, Phase II Clinical Study Evaluating the Combination Therapy of 
 Sacituzumab Tirumotecan in Patients With Unresectable\, Locally Advanced\,
  Recurrent\, or Metastatic Esophageal Squamous Cell Carcinoma\nEstimated p
 rimary completion: December 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07128693
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07823270-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07823270)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Neoadjuvant Sacituzu
 mab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous C
 ell Carcinoma\nEstimated primary completion: December 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07823270
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662863-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07662863)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Bladder Cancer.\nStudy: Sac
 ituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-
 SPARE-UC-01)\nEstimated primary completion: 1 December 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07662863
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07819578-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07819578)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy f
 or Resectable NSCLC\nEstimated primary completion: 1 December 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0781957
 8
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07720258-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07720258)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Sacituzumab Tirumote
 can (MK-2870) in Patients With Advanced Small Bowel Adenocarcinoma Refract
 ory or Intolerant to Platinum-Based Combination Therapy\nEstimated primary
  completion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07720258
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07907861-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07907861)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Sacituzumab Tirumote
 can Plus Toripalimab for Advanced Penile Cancer After Platinum Chemotherap
 y\nEstimated primary completion: 1 January 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07907861
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06422143-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20290112
DTEND;VALUE=DATE:20290113
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06422143)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan
  (Sac-TMT\; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NS
 CLC) [MK-2870-023]\nEstimated primary completion: 12 January 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06422143
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06824467-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20290427
DTEND;VALUE=DATE:20290428
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06824467)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Ovarian Cancer.\nStudy: A S
 tudy to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-28
 70) Maintenance Treatment Versus Standard of Care in Participants With Pla
 tinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov
 84/GOG-3103)\nEstimated primary completion: 27 April 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06824467
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07419295-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20290727
DTEND;VALUE=DATE:20290728
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT07419295)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Bladder Cancer.\nStudy: A C
 linical Trial of Sacituzumab Tirumotecan (Sac-TMT\, MK-2870) to Treat Urot
 helial Cancer (MK-2870-031)\nEstimated primary completion: 27 July 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumoteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 419295
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07738341-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Sacituzumab Tirumotecan: Phase 1/2 readout est. (NCT07738341)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1/2\, HR+/HER2- Metastatic Brea
 st Cancer.\nStudy: GB268 Monotherapy or Combination Therapy for Locally Ad
 vanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)\nEstimated primary completi
 on: 1 August 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sa
 cituzumab-tirumotecan#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07738341
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286149-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20290817
DTEND;VALUE=DATE:20290818
SUMMARY:Sacituzumab Tirumotecan: Phase 1/2 readout est. (NCT07286149)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1/2\, Non-Small Cell Lung Cance
 r.\nStudy: A Clinical Study of MK-1084 With Other Treatments for Non-small
  Cell Lung Cancer (MK-3475-01F)\nEstimated primary completion: 17 August 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tiru
 motecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07286149
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07750704-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07750704)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Gui
 dance as First-Line Therapy for ALK Fusion-Positive NSCLC\nEstimated prima
 ry completion: September 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07750704
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06469944-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20290912
DTEND;VALUE=DATE:20290913
SUMMARY:Sacituzumab Tirumotecan: Phase 1/2 readout est. (NCT06469944)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1/2.\nStudy: Substudy 06C: A St
 udy of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherap
 y in Participants With First-Line Locally Advanced Unresectable/Metastatic
  Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)\nEstimated pri
 mary completion: 12 September 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06469944
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07716917-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07716917)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Genitourinary Tumors
  With Sacituzumab Tirumotecan\nEstimated primary completion: October 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumote
 can#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07716917
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06428409-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20291016
DTEND;VALUE=DATE:20291017
SUMMARY:Sacituzumab Tirumotecan: Phase 1/2 readout est. (NCT06428409)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1/2.\nStudy: A Clinical Study o
 f MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers
  (MK-9999-02A)\nEstimated primary completion: 16 October 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06428409
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07252739-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20291115
DTEND;VALUE=DATE:20291116
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07252739)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 
 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat S
 arcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-
 U01J)\nEstimated primary completion: 15 November 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07252739
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07586943-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Sacituzumab Tirumotecan: Phase 1/2 readout est. (NCT07586943)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1/2.\nStudy: SKB118 Injection i
 n Advanced Solid Tumors\nEstimated primary completion: December 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07586
 943
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07750353-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07750353)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: A Phase II\, Investi
 gator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previousl
 y Treated Unresectable Thymic Carcinomas\nEstimated primary completion: De
 cember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzu
 mab-tirumotecan#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07750353
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07913568-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07913568)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: A Phase II Investiga
 tor-initiated Trial of Sacituzumab Tirumotecan Plus Pembrolizumab in Patie
 nts With Recurrent ovarIan Clear Cell Carcinoma Previously Treated With Pl
 atinum-based Chemotherapy（NCCH2407/MK014）\nEstimated primary completio
 n: 31 January 2030. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 acituzumab-tirumotecan#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07913568
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07804966-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07804966)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Sac-TMT in Vaginal a
 nd Vulvar Cancers\nEstimated primary completion: March 2030. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07804966
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07628504-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20300330
DTEND;VALUE=DATE:20300331
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT07628504)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Breast Cancer.\nStudy: Sac-
 TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk T
 riple-Negative Breast Cancer Without BRCA Mutations\nEstimated primary com
 pletion: 30 March 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07628504
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07639086-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07639086)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Sacituzumab Tirumote
 can in Pts w/ NEPC After Progression on Prior Chemotherapy\nEstimated prim
 ary completion: 31 March 2030. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07639086
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07928193-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07928193)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Sac-TMT in Salivary 
 Gland Cancers\nEstimated primary completion: April 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07928193
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06841354-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20300518
DTEND;VALUE=DATE:20300519
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06841354)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Breast Cancer.\nStudy: A St
 udy of Sacituzumab Tirumotecan (Sac-TMT\, MK-2870) as Monotherapy and in C
 ombination With Pembrolizumab (MK-3475) in Participants With Triple-Negati
 ve Breast Cancer (MK-2870-011/TroFuse-011)\nEstimated primary completion: 
 18 May 2030. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzu
 mab-tirumotecan#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06841354
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06393374-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20301216
DTEND;VALUE=DATE:20301217
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06393374)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Breast Cancer.\nStudy: Saci
 tuzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Di
 d Not Achieve pCR (MK-2870-012)\nEstimated primary completion: 16 December
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-ti
 rumotecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06393374
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07511023-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20310301
DTEND;VALUE=DATE:20310302
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07511023)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Phase 2 Trial Of Sac
 ituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectabl
 e Squamous Cell Carcinoma Of The Anus/Rectum\nEstimated primary completion
 : 1 March 2031. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacit
 uzumab-tirumotecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07511023
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07785609-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07785609)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: A Clinical Trial of 
 MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid 
 Tumors (MK-2010)\nEstimated primary completion: 30 September 2031. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07785609
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07216703-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20311029
DTEND;VALUE=DATE:20311030
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT07216703)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Cervical Cancer.\nStudy: A 
 Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pe
 mbrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc
 er (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)\nEstimated primary comple
 tion: 29 October 2031. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/sacituzumab-tirumotecan#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07216703
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07829783-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20311117
DTEND;VALUE=DATE:20311118
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT07829783)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Bladder Cancer.\nStudy: A C
 linical Trial of Sacituzumab Tirumotecan (Sac-TMT\, MK-2870) and Pembroliz
 umab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)\nEstimat
 ed primary completion: 17 November 2031. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07829783
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780111-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20320104
DTEND;VALUE=DATE:20320105
SUMMARY:Sacituzumab Tirumotecan: Phase 1/2 readout est. (NCT06780111)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1/2.\nStudy: Substudy 06E: Umbr
 ella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYM
 AKER-U06)\nEstimated primary completion: 4 January 2032. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06780111
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06788912-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20320206
DTEND;VALUE=DATE:20320207
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT06788912)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable
  Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)\nEstimated 
 primary completion: 6 February 2032. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06788912
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952504-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20320524
DTEND;VALUE=DATE:20320525
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06952504)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Endometrial Cancer.\nStudy:
  A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With 
 Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Partici
 pants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroF
 use-033/GOG-3119/ENGOT-en29)\nEstimated primary completion: 24 May 2032. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumoteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 952504
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07908524-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20320629
DTEND;VALUE=DATE:20320630
SUMMARY:Sacituzumab Tirumotecan: Phase 1/2 readout est. (NCT07908524)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1/2.\nStudy: MK-2870-U01 Substu
 dy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer
  (MK-2870-01A)\nEstimated primary completion: 29 June 2032. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07908524
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318558-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20330225
DTEND;VALUE=DATE:20330226
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT07318558)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Ovarian Cancer.\nStudy: A C
 linical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian 
 Cancer (MK-2870-021)\nEstimated primary completion: 25 February 2033. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07318
 558
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06966700-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20330323
DTEND;VALUE=DATE:20330324
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06966700)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Breast Cancer.\nStudy: A Cl
 inical Study of Sacituzumab Tirumotecan (Sac-TMT\, MK-2870) in People With
  Breast Cancer (MK-2870-032)\nEstimated primary completion: 23 March 2033.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumote
 can#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06966700
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06312137-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20340221
DTEND;VALUE=DATE:20340222
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06312137)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study to Assess Efficacy and Safety of Pembrolizumab With or Wi
 thout Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resect
 able Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complet
 e Response (pCR) (MK-2870-019)\nEstimated primary completion: 21 February 
 2034. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tir
 umotecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06312137
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07718854-1991@assetmemo.bio
DTSTAMP:20261121T005957Z
DTSTART;VALUE=DATE:20360930
DTEND;VALUE=DATE:20361001
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07718854)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Ovarian Cancer.\nStudy: Sac
 ituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurr
 ent Ovarian Clear Cell Cancer\nEstimated primary completion: September 203
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumo
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07718854
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
